

KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]

Regd. Office: Office No. 904, 9th Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, India

E-mail : info@kamronlabs.com



KAMRON

30th May, 2019

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001

Company Code No. 524604

Dear Sir,

Sub: Outcome of Board Meeting and Submission of Audited Financial Results for the year ended on 31st March, 2019

We refer to our letter dated 7th May, 2019 informing the date of Meeting of the Board of Directors of the Company.

Please note that the Board of Directors in their meeting held on 30th May, 2019, have approved the Standalone Audited Financial Results for the financial year 2018-19 ended on 31st March, 2019.

Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, we are enclosing herewith:

1. Statement of Audited Financial Results for the year ended on 31st March, 2019.
2. Auditors' Report on the Audited Financial Results
3. Declaration to the effect that there is Unmodified Opinion with respect to Audited Financial Results for the year ended on 31st March, 2019.

Thanking you,

Yours faithfully,

For KAMRON LABORATORIES LIMITED

Kamlesh J. Laskari

KAMLESH J. LASKARI
MANAGING DIRECTOR



Encl: As above.

KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]


Regd. Office: Office No. 904, 9th Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, IndiaE-mail : info@kamronlabs.com**KAMRON****STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS
FOR THE QUARTER/ YEAR ENDED ON 31ST MARCH, 2019**

(Rs. in Lakh)

Particulars	Quarter ended on			Year ended on	
	31-03-2019 (Audited)	31-12-2018 (Unaudited)	31-03-2018 (Audited)	31-03-2019 (Audited)	31-03-2018 (Audited)
(Refer Notes Below)					
1 Revenue from operations	104.84	108.38	194.92	559.42	817.01
2 Other income	13.29	10.25	17.67	24.89	21.47
3 Total Income (1+2)	118.13	118.63	212.59	584.31	838.48
4 Expenses					
a. Cost of Materials consumed	21.83	1.51	128.01	95.76	363.63
b. Purchases of stock-in-trade	36.65	68.53	-	150.56	140.30
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(199.58)	(28.83)	(8.51)	(103.87)	(42.82)
d. Employee benefits expense	30.30	33.37	27.12	151.62	138.97
e. Finance costs	1.65	0.22	(6.89)	7.27	33.65
f. Depreciation & amortisation expense	18.41	17.84	29.02	73.44	72.91
g. Other expenses	25.32	56.65	35.12	206.49	130.41
Total Expenses	(65.42)	149.29	203.87	581.27	837.05
5 Profit / (Loss) before exceptional items and tax (3-4)	183.55	(30.66)	8.72	3.04	1.43
6 Exceptional items	-	-	-	-	-
7 Profit / (Loss) before tax (5-6)	183.55	(30.66)	8.72	3.04	1.43
8 Tax expense:					
Current tax	-	-	-	-	-
Deferred tax / Earlier Year	0.28	-	1.25	0.28	1.25
9 Profit (Loss) for the period from continuing operations (7-8)	183.27	(30.66)	7.47	2.76	0.18
10 Profit/(loss) from discontinuing operations before Tax	-	-	-	-	-
11 Tax expense of discontinuing operations	-	-	-	-	-
12 Profit/(loss) from Discontinuing operations (after tax) (10-11)	-	-	-	-	-
13 Profit / (Loss) for the period (9+12)	183.27	(30.66)	7.47	2.76	0.18

FOR, KAMRON LABORATORIES LTD. †

Kamrun Lalani
MANAGING DIRECTOR



KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]


Regd. Office: Office No. 904, 9th Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, IndiaE-mail : info@kamronlabs.com**KAMRON**

(Rs. in Lakh)

Particulars	Quarter ended on			Year ended on	
	31-03-2019	31-12-2018	31-03-2018	31-03-2019	31-03-2018
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
14 Other Comprehensive Income					
<i>Items that will not be reclassified subsequently to profit or loss</i>	-	-	-	-	-
Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
<i>Items that will be reclassified subsequently to profit or loss</i>	-	-	-	-	-
Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
Other Comprehensive Income, net of tax	-	-	-	-	-
15 Total Comprehensive Income for the period (13+14)	183.27	(30.66)	7.47	2.76	0.18
16 Paid-up equity shares capital (Face Value per share Rs. 10)	585.00	585.00	585.00	585.00	585.00
17 Reserves excluding Revaluation Reserves	-	-	-	112.84	110.08
18 Earnings Per Share of Rs.10 each (for continuing operations)					
- Basic	3.13	-	0.13	0.05	-
- Diluted	3.13	-	0.13	0.05	-
19 Earnings Per Share of Rs.10 each (for discontinued operations)					
- Basic	-	-	-	-	-
- Diluted	-	-	-	-	-
20 Earnings Per Share of Rs.10 each (for discontinued & continuing operations)					
- Basic	3.13	-	0.13	0.05	-
- Diluted	3.13	-	0.13	0.05	-

FOR, KAMRON LABORATORIES LTD.

Kamron Laboratories
MANAGING DIRECTOR



KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]


Regd. Office: Office No. 904, 9th Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, IndiaE-mail : info@kamronlabs.com**STATEMENT OF ASSETS AND LIABILITIES**

(Rs. in Lakh)

Sr. No.	Particulars	As at 31-03-2019	As at 31-03-2018
	ASSETS		
1	Non-Current Assets		
	Property, plant and equipment	1137.61	1187.02
	Capital work-in-progress	-	-
	Investment property	-	-
	Goodwill	-	-
	Other intangible Assets	60.92	58.45
	Intangible Assets under development	-	-
	Biological Assets other than bearer plants	-	-
	Non-Current Financial Assets:		
	(i) Investments, Non-Current	-	-
	(ii) Trade receivables, Non-Current	-	-
	(iii) Loans, Non-Current	3.57	5.61
	Deferred tax Assets (net)	-	-
	Other Non-Current Assets	-	-
	Total Non-Current Assets	1202.10	1251.08
2	Current Assets		
	Inventories	323.82	229.06
	Current financial asset:		
	(i) Current investments	-	-
	(ii) Trade receivables, Current	208.16	227.85
	(iii) Cash and cash equivalents	16.96	13.62
	(iv) Bank balance other than above	-	154.77
	(v) Loans, Current	6.72	17.09
	(vi) Other Current financial Assets	-	-
	Current tax Assets (net)	-	-
	Other Current Assets	426.81	442.29
	Total Current Assets	982.47	1084.69
	TOTAL ASSETS	2184.57	2335.77

FOR, KAMRON LABORATORIES LTD.

Kamlesh I. Lonkar
MANAGING DIRECTOR



KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]

Regd. Office: Office No. 904, 9th Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, IndiaE-mail : info@kamronlabs.com**KAMRON**

(Rs. in Lakh)

EQUITY AND LIABILITIES			
1	Equity		
	Equity share capital	585.00	585.00
	Other Equity	118.26	117.52
	Total Equity	703.26	702.52
2	Liabilities		
	Non-Current Liabilities		
	Non-Current financial Liabilities:		
	(i) Borrowings, Non-Current	-	376.77
	(ii) Trade payables, Non-Current		
	(a) total outstanding dues of micro enterprises and small enterprises	-	-
	(b) total outstanding dues of creditors other than micro enterprises and small enterprises	-	-
	(iii) Other Non-Current financial Liabilities	-	-
	Provisions, Non-Current	24.68	24.40
	Deferred tax Liabilities (net)	4.59	4.59
	Other Non-Current Liabilities	-	-
	Total Non-Current Liabilities	29.27	405.76
	Current Liabilities		
	Current financial Liabilities:		
	(i) Borrowings, Current	535.15	755.05
	(ii) Trade payables, Current		
	(a) total outstanding dues of micro enterprises and small enterprises	-	-
	(b) total outstanding dues of creditors other than micro enterprises and small enterprises	169.52	80.39
	(iii) Other Current financial Liabilities	-	-
	Other Current Liabilities	746.78	391.65
	Provisions, Current	0.59	0.40
	Current tax Liabilities (Net)	-	-
	Total Current Liabilities	1452.04	1227.49
	Total Liabilities	1481.31	1633.25
	TOTAL EQUITY AND LIABILITIES	2184.57	2335.77

FOR, KAMRON LABORATORIES LTD.

Kamlesh Kantan
MANAGING DIRECTOR



KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]

Regd. Office: Office No. 904, 9th Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, India

E-mail : info@kamronlabs.com



KAMRON

Notes:

1	The figures for quarter ended on 31 st March, 2019 are the balancing figures between the audited figures in respect of the full financial year ended on 31 st March, 2019 and the year to date figures upto the third quarter of the financial year.
2	The Company is operating only in one segment i.e. Pharma. Hence segment reporting is not given.
3	The Company does not have any subsidiary / associate.
4	Figures, wherever required, are regrouped / rearranged. There are no material adjustments made in the results of the earlier periods.
5	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 30th May, 2019
6	The Statutory Auditors have carried out an audit of the above results for the financial year ended 31 st March, 2019 and have issued an unmodified opinion on the same.

For, KAMRON LABORATORIES LIMITED

Date : 30th May, 2019

Place : Ahmedabad



Kamlesh J. Laskari

KAMLESH J. LASKARI
MANAGING DIRECTOR



**INDEPENDENT AUDITORS' REPORT
TO THE BOARD OF DIRECTORS OF KAMRON LABORATORIES LIMITED**

1. We have audited the accompanying Statement of Financial Results of Kamron Laboratories Limited. ("the Company") for the financial year ended 31st March, 2019 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on audit of such Financial Statements.

2. We conducted our audit in accordance with the Standards of Auditing issued by the Institute of Chartered Accountants of India. This standard requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance as to whether the financial statements are free of material misstatement.


An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

3. Based on our audit conducted as above, in our opinion, and to the best of our information and according to the explanations given to us, the Statement:
- (i) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016; and
- (ii) gives a true and fair view in conformity with the aforesaid Ind-AS and other accounting principles generally accepted in India of the net profit, total comprehensive income and other financial information of the Company for the year ended 31st March 2019.
4. The Statement includes the results for the Quarter ended 31st March 2019 being the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For **RANGWALA & CO**
Chartered Accountants
(Firm's Registration No. 115833W)



Ahmedabad, 30th May, 2019


(RAHUL P DOSHI)
Partner
(Membership No. 117160)

KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]

Regd. Office: Office No. 904, 9th Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, India

E-mail : info@kamronlabs.com



KAMRON

30th May, 2019

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

Company Code No. 524604

Dear Sir,

Sub: Declaration regarding Audit report with unmodified opinion with respect to Annual Audited Financial Results for the Financial Year ended 31st March, 2019

Pursuant to Regulation 33(3) (d) of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, and SEBI Circular No.CIR/CFD/CMD/56/2016 dated 27th May, 2016, it is hereby declared and confirmed that Auditors' Report obtained from M/s. Rangwala & Co., Chartered Accountant, Ahmedabad on Annual Audited Financial Results of the Company for the financial year ended 31st March, 2019 has an unmodified opinion.

Kindly take the above information on record.

Thanking you,

Yours faithfully,
For KAMRON LABORATORIES LIMITED

Kamlesh J. Laskari

KAMLESH J. LASKARI
MANAGING DIRECTOR

